Quality of life in patients with non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: a systematic review and meta-analysis

BACKGROUND: Immune checkpoint inhibitors (ICIs) have dramatically prolonged survival in non-small cell lung cancer (NSCLC) patients, but little research had focused on its impact on quality of life (QoL). The purpose of our study was to compare the QoL in patients with NSCLC treated with programmed...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Wei, Zhang, Qian, Zhang, Tiantian, Li, Li, Xu, Chunhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531439/
https://www.ncbi.nlm.nih.gov/pubmed/36192730
http://dx.doi.org/10.1186/s12957-022-02800-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531439/
https://www.ncbi.nlm.nih.gov/pubmed/36192730
http://dx.doi.org/10.1186/s12957-022-02800-1

Ejemplares similares